SPDR S&P Biotech ETF
227 hedge funds and large institutions have $3.11B invested in SPDR S&P Biotech ETF in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 70 increasing their positions, 60 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
13% more funds holding
Funds holding: 201 → 227 (+26)
6.53% more ownership
Funds ownership: 112.16% → 118.69% (+6.5%)
31% less call options, than puts
Call options by funds: $724M | Put options by funds: $1.04B
Holders
227
Holding in Top 10
6
Calls
$724M
Puts
$1.04B
Top Buyers
| 1 | +$166M | |
| 2 | +$99.4M | |
| 3 | +$83.3M | |
| 4 |
Barclays
London,
United Kingdom
|
+$40.6M |
| 5 |
Morgan Stanley
New York
|
+$38.9M |
Top Sellers
| 1 | -$108M | |
| 2 | -$49.5M | |
| 3 | -$40.3M | |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$26.6M |
| 5 |
Rafferty Asset Management
New York
|
-$17.1M |